For decades, pancreatic cancer has stood among the most feared diagnoses in medicine, aggressive, hard to detect early, and stubbornly resistant to treatment. A new drug is now offering something that has long seemed out of reach: meaningfully longer survival, by hitting a target scientists once considered impossible to drug.
A new drug called daraxonrasib targets the KRAS mutation that fuels most pancreatic tumors, something many scientists once thought couldn’t be done, and in a major clinical trial, nearly doubled survival for patients with advanced disease. The KRAS gene, when mutated, drives the uncontrolled growth behind a large share of pancreatic cancers, but its structure makes it notoriously difficult for drugs to bind to. Cracking that target represents a milestone that researchers have pursued for a generation.
The significance extends beyond a single drug. Pancreatic cancer’s lethality stems partly from how few effective options have existed; a treatment that substantially extends survival in advanced cases could reshape the standard of care and open the door to combination approaches that build on it.
The breakthrough arrived during a remarkably productive stretch for science across multiple fields. In cancer research more broadly, scientists uncovered a surprising new way the immune system fights cancer, overturning a core belief that has guided immunology for decades. Researchers also continued probing the limits of widely used metabolic drugs: a study identified genetic variants, carried by roughly 10% of the population, that may cause a form of “GLP-1 resistance,” making some people less responsive to popular diabetes and weight-loss drugs.
Elsewhere, discoveries spanned the planet and the periodic table. Scientists discovered a vast hidden structure beneath East Antarctica’s ice, a giant fan-shaped network of basins, revealing that several known subglacial features are part of one massive geological formation. In physics and engineering, researchers at EPFL shrank a powerful ultrafast laser onto a chip after 20 years of effort, achieving performance on par with tabletop femtosecond lasers in a form that could make the technology far smaller and cheaper.
Each of these advances shares a common thread: problems long considered intractable yielding to persistent research and new tools. For pancreatic cancer patients and their families, daraxonrasib’s results offer something especially precious, not a cure, but real, measurable additional time, and the momentum of a field that has finally found a way into a target it spent decades unable to touch.
As with all clinical findings, longer-term data and broader trials will be needed to fully establish the drug’s role. But the direction is unmistakable, and for a disease that has resisted progress for so long, that direction points, at last, toward hope.